TORONTO, March 04, 2021 (GLOBE NEWSWIRE) -- Harvest Portfolios Group Inc. (“Harvest”) is pleased to announce that Big Pharma Split Corp. (the “Company”) has completed the overnight offering of Preferred Shares and Class A Shares of the Company. Total gross proceeds of the offering were $9.3 million, bringing the Company’s net assets to approximately $30.5 million. The shares will trade on the Toronto Stock Exchange under the existing symbols of PRM.PR.A (Preferred Shares) and PRM (Class A Shares). The Preferred Shares were offered at a price of $10.50 per Preferred Share to yield 4.8% and the Class A Shares were offered at a price of $13.75 per Class A Share to yield 9.0%. The offering was co-led by BMO Capital Markets, CIBC World Markets Inc. and Scotia Capital Inc., and also included National Bank Financial Inc., TD Securities Inc., Canaccord Genuity Corp., Hampton Securities Limited, Raymond James Ltd., Richardson Wealth Limited, Desjardins Securities Inc., Echelon Wealth Partners Inc., iA Private Wealth Inc., Mackie Research Capital Corporation and Manulife Securities Incorporated. The net proceeds of the offering will be used to invest in an equally-weighted portfolio of ten issuers comprised of equity securities selected by Harvest from a universe of pharmaceutical issuers which includes: Eli Lilly and Company | Johnson & Johnson | Amgen Inc. | Novartis AG | Pfizer Inc. AstraZeneca PLC | Sanofi SA | Merck & Co Inc. | Bristol-Myers Squibb Company | AbbVie Inc. In order to seek to generate additional returns, Harvest may write call options each month in respect of some or all of the equity securities in the portfolio. Harvest is the manager, portfolio manager and promoter of the Company. For additional information: Please visit www.harvestportfolios.com, e-mail [email protected] or call toll free 1-866-998-8298. About Harvest Portfolios Group Inc. Founded in 2009, Harvest is a Canadian Investment Fund Manager managing over $1.25 billion in assets for Canadian Investors. Harvest offers an innovative suite of exchange traded funds, mutual funds and publicly-listed structured fund products designed to satisfy the long-term growth and income needs of investors. We pride ourselves in creating trusted investment solutions that meet the expectations of our investors. Commissions, management fees and expenses all may be associated with investment fund investments. Investors should read the prospectus supplement to the Company’s short form base shelf prospectus dated November 4, 2020 before investing. Investment funds are not guaranteed, their values change frequently, and past performance may not be repeated. Please read the Company’s publicly filed documents which are available at www.sedar.com.
Harvest Portfolios Group Inc. Completes $9.3 million Overnight Offering for Big Pharma Split Corp.
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...